thromboxane synthase

Dazoxiben is an orally active thromboxane synthase inhibitor.

A thromboxane synthase (TxAS) has also been identified.

Dipyridamole blocks the thromboxane synthase as well as the thromboxane receptor.

Some studies have in fact revealed that TP receptor antagonists are more effective than thromboxane synthase inhibitors.

Picotamide has activity both as a thromboxane synthase inhibitor and as a thromboxane receptor antagonist.

In 1975, at the Wellcome Research Laboratories, he led the team that discovered the enzyme thromboxane synthase and the vasodilator prostacyclin.

Thromboxane synthetase is an older, more Latin appropriate name for thromboxane synthase often found in the literature, but convention has moved to shortening of many such terms.

Thromboxane synthase inhibitors inhibit the final enzyme (thromboxane synthase) in the synthesis of thromboxane.

It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor.

Of special importance are the cytochrome P450 enzymes in animals, including CYP5A1 (thromboxane synthase), CYP8A1 (prostacyclin synthase), and the CYP74 family of hydroperoxide-metabolizing enzymes in plants, lower animals and bacteria.